SCHEMBL253023

SCHEMBL253023

C[C@@H](O)[C@H](O)c1ccccc1I

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.42
SLC6A2 P23975 3/20 0.42
CYP2D6 P10635 3/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
KCNH2 Q12809 1/20 0.42
GABRA1 P14867 3/20 0.38
GABRB2 P47870 2/20 0.38
LMNA P02545 2/20 0.35
HIF1A Q16665 2/20 0.35
ADRA2C P18825 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ADRA2A P08913 1/20 0.35
TSHR P16473 3/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
FAAH O00519 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29528605 1.00 CYP3A4 (0.42) CYP3A4SLC6A2CYP2D6SLC6A4SLC6A3
SCHEMBL251912 1.00 CYP3A4 (0.42) CYP3A4SLC6A2CYP2D6SLC6A4SLC6A3
SCHEMBL29528763 1.00 CYP3A4 (0.42) CYP3A4SLC6A2CYP2D6SLC6A4SLC6A3
SCHEMBL251913 1.00 CYP3A4 (0.42) CYP3A4SLC6A2CYP2D6SLC6A4SLC6A3
SCHEMBL251914 1.00 CYP3A4 (0.42) CYP3A4SLC6A2CYP2D6SLC6A4SLC6A3
SCHEMBL253024 1.00 CYP3A4 (0.42) CYP3A4SLC6A2CYP2D6SLC6A4SLC6A3
SCHEMBL11606150 0.88 CYP3A4 (0.44) CYP3A4SLC6A2CYP2D6SLC6A4SLC6A3
SCHEMBL15050440 0.83 CYP3A4 (0.40) CYP3A4SLC6A2CYP2D6SLC6A4SLC6A3
SCHEMBL15050710 0.83 CYP3A4 (0.40) CYP3A4SLC6A2CYP2D6SLC6A4SLC6A3
SCHEMBL15050443 0.83 CYP3A4 (0.40) CYP3A4SLC6A2CYP2D6SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423433-B1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES BIO PHARM SOLUTIONS CO LTD (KR) 2025-12-17 EP disclosed
EP-2970112-B1 PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME BIO PHARM SOLUTIONS CO LTD (KR) 2025-03-12 EP disclosed
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-03-19 US disclosed
EP-4204395-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-05 EP disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
US-10525030-B2 Phenyl carbamate compound and a composition for neuroprotection comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2020-01-07 US disclosed
US-10525030-B2 Phenyl carbamate compound and a composition for neuroprotection comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2020-01-07 US disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
EP-2590936-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME Bio-Pharm Solutions Co., Ltd. (KR) 2013-05-15 EP disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
WO-2012096458-A2 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 WO disclosed
WO-2012002773-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-01-05 WO disclosed
WO-2012002773-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses STS, SULT2A1, SULT1A1 CYP3A4 1003/4885SLC6A2 17/4885CYP2D6 871/4885
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME CPT1B, MYLK, PYGM CYP3A4 211/4885SLC6A2 1277/4885CYP2D6 841/4885
US-10525030-B2 Phenyl carbamate compound and a composition for neuroprotection comprising the same CHAT, BAX, CASP3 CYP3A4 3847/4885SLC6A2 871/4885CYP2D6 4531/4885
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease SNCA, MAPT, CHAT CYP3A4 4695/4885SLC6A2 1757/4885CYP2D6 4798/4885
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES CPS1, BCHE, ACHE CYP3A4 11/4885SLC6A2 1019/4885CYP2D6 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.